CCL2 and neoplasm: Considering our results on tumor immunity, IL-17A at local tumor sites presumably induces MDSCs through IL-6 and CCL2, recruits Treg cells and directly inhibits Th1 functions or indirectly suppresses Th1 functions by MDSCs and Treg cells, finally resulting in anergy and dysfunction of CTLs in tumor sites.